Anshan Tumor Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02203253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Anshan Tumor Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Nausea (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 8